Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk (TIERRA)

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: April 1, 2009
Last updated: February 12, 2013
Last verified: February 2013
Evaluate satisfaction in people treated with IPDE5 inhibitors over time

Condition Phase
Erectile Dysfunction
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Satisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event.

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • EDITS [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • SEAR [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Medication prescribed [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 720
Study Start Date: December 2007
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
filling in questionnaires

Detailed Description:
12 first patients that are eligible

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
People with cv risk

Inclusion Criteria:

  • CV risk factors
  • Male above 18

Exclusion Criteria:

  • Non-informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00874185

Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT00874185     History of Changes
Other Study ID Numbers: A1481256 
Study First Received: April 1, 2009
Last Updated: February 12, 2013
Health Authority: Spain: Ethics Committee

Keywords provided by Pfizer:

Additional relevant MeSH terms:
Erectile Dysfunction
Genital Diseases, Male
Mental Disorders
Sexual Dysfunction, Physiological
Sexual Dysfunctions, Psychological
Phosphodiesterase 5 Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Phosphodiesterase Inhibitors processed this record on May 30, 2016